MaxCyte Historical Income Statement
| MXCT Stock | USD 3.52 0.14 4.14% |
Historical analysis of MaxCyte income statement accounts such as Selling And Marketing Expenses of 28.3 M can show how well MaxCyte performed in making a profits. Evaluating MaxCyte income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of MaxCyte's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining MaxCyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MaxCyte is a good buy for the upcoming year.
MaxCyte |
About MaxCyte Income Statement Analysis
MaxCyte Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to MaxCyte shareholders. The income statement also shows MaxCyte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
MaxCyte Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts MaxCyte generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of MaxCyte minus its cost of goods sold. It is profit before MaxCyte operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from MaxCyte's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into MaxCyte current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.At this time, MaxCyte's Reconciled Depreciation is comparatively stable compared to the past year. Interest Income is likely to gain to about 10 M in 2024, whereas Gross Profit is likely to drop slightly above 19.4 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.0M | 126.9K | 145.9K | 138.6K | Depreciation And Amortization | 1.4M | 2.7M | 4.2M | 4.4M |
MaxCyte income statement Correlations
Click cells to compare fundamentals
MaxCyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MaxCyte income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 819.6K | 1.0M | 1.4M | 2.7M | 4.2M | 4.4M | |
| Interest Expense | 681.1K | 825.6K | 1.0M | 126.9K | 145.9K | 138.6K | |
| Selling General Administrative | 6.1M | 8.4M | 18.7M | 25.8M | 30.1M | 31.6M | |
| Selling And Marketing Expenses | 7.9M | 8.3M | 13.0M | 18.7M | 27.0M | 28.3M | |
| Total Revenue | 21.6M | 26.2M | 33.9M | 44.3M | 41.3M | 21.9M | |
| Gross Profit | 19.1M | 23.4M | 30.2M | 39.2M | 36.5M | 19.4M | |
| Other Operating Expenses | 34.0M | 37.2M | 52.1M | 71.6M | 89.6M | 94.1M | |
| Operating Income | (12.4M) | (11.1M) | (18.2M) | (27.4M) | (48.3M) | (45.9M) | |
| Ebit | (12.4M) | (11.0M) | (18.2M) | (23.6M) | (48.3M) | (45.9M) | |
| Research Development | 17.6M | 17.7M | 15.4M | 19.5M | 23.8M | 12.0M | |
| Ebitda | (11.6M) | (9.9M) | (16.8M) | (20.9M) | (44.1M) | (41.9M) | |
| Cost Of Revenue | 2.5M | 2.8M | 3.6M | 5.1M | 4.7M | 2.5M | |
| Total Operating Expenses | 31.5M | 34.5M | 48.4M | 66.5M | 84.8M | 89.1M | |
| Income Before Tax | (12.9M) | (11.8M) | (19.1M) | (23.6M) | (37.9M) | (36.0M) | |
| Total Other Income Expense Net | (475K) | (759.7K) | (893.6K) | 3.8M | 10.4M | 10.9M | |
| Net Income | (13.6M) | (12.6M) | (20.1M) | (19.8M) | (37.9M) | (36.0M) | |
| Income Tax Expense | 681.1K | 825.6K | 1.0M | (3.8M) | 4.0M | 4.2M | |
| Net Interest Income | (475K) | (759.7K) | (893.6K) | 3.8M | 9.4M | 9.9M | |
| Net Income From Continuing Ops | (12.9M) | (11.8M) | (19.1M) | (23.6M) | (37.5M) | (35.6M) | |
| Reconciled Depreciation | 613.5K | 1.0M | 1.4M | 2.7M | 4.0M | 4.2M | |
| Net Income Applicable To Common Shares | (12.9M) | (11.8M) | (19.1M) | (23.6M) | (21.2M) | (22.3M) | |
| Interest Income | 206.1K | 65.9K | 150.8K | 3.9M | 9.5M | 10.0M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.